Kamesha Moultry
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,144, 3.0 times the $379 reported in 2021.
Across 140 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$508
- Otsuka America Pharmaceutical, Inc.$391
- Vanda Pharmaceuticals Inc.$384
- GSK$248
- AbbVie$194
- Teva Pharmaceuticals USA, Inc.$184
- plus $686 from 11 others
What the payments were for
- Food & beverage$2,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 24 | $508 |
| Otsuka America Pharmaceutical, Inc. | 19 | $391 |
| Vanda Pharmaceuticals Inc. | 18 | $384 |
| GSK | 21 | $248 |
| AbbVie | 12 | $194 |
| Teva Pharmaceuticals USA, Inc. | 9 | $184 |
| Alkermes, Inc. | 7 | $147 |
| Johnson & Johnson | 6 | $146 |
| AstraZeneca | 6 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $95 |
| Lundbeck LLC | 5 | $77 |
| Merck | 3 | $37 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| KCI USA, Inc. | 1 | $13 |
How this compares
$2,596 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 119 | $363,205 |
| IngrezzaValbenazine Tosylate | 15 | $123,126 |
| Abilify MaintenaAripiprazole | 32 | $94,858 |
| AustedoDeutetrabenazine | 17 | $87,335 |
| RexultiBrexpiprazole | 26 | $39,107 |
| CaplytaLumateperone Tosylate | 21 | $35,677 |
| AristadaAripiprazole Lauroxil | 11 | $34,830 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,315 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,955 |
| Haloperidol Decanoate | 85 | $4,271 |
| Paliperidone ErPaliperidone | 20 | $3,673 |
| Haloperidol | 102 | $3,153 |
| Fluphenazine Decanoate | 38 | $3,080 |
| Ziprasidone Hcl | 34 | $2,804 |
| Quetiapine Fumarate | 109 | $2,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $146 | $363,205119 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $391 | $133,96558 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $508 | $123,12615 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $184 | $87,33517 claims |
| Alkermes, Inc.Aristada, Lybalvi | $147 | $57,14525 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $95 | $35,67721 claims |
| Lilly USA, LLCOlanzapine | $19 | $1,669116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Ozark
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.